Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
82.5
譲渡前の議決権所有割合（％）Wording
Conditional
How definitive the wording is.This transaction
Share transferCounterparty加藤俊也氏
Disclosing companyMedical Net,Inc.
TimelineThe spacing between the points is proportional to the actual number of days.1 day from 決議 / 締結 to 実行.White points represent dates designated as scheduled dates in the document.
Target company
Contract Clinical Testing
Location Minami-ku, Hiroshima, Hiroshima PrefectureShare capital 12,500万円Date of incorporation 3 September 2012
Net Sales25,880千円（2024年５月期）
Operating profit△66,125千円（2024年５月期）
Net income for the current fiscal year△65,266千円（2024年５月期）
Net assets△141,522千円（2024年５月期）
Consideration and expenses
Acquisition price譲渡価額：非公表とさせていただきます（株主が個人であり、株式譲渡契約書における守秘義務をふまえ）
Impact on Business Performance
現在精査中であり、他の要因も含め、見通しが明らかになり次第、速やかに公表いたします。
Procedures and assumptions
Valuation methodology公正なプロセスを経て株式譲渡相手先との交渉により決定
| Item | Details |
|---|---|
| Transaction name | Share transfer |
| Counterparty name | 加藤俊也氏 |
| Name of the Subject Company | 株式会社ミルテル |
| Business Description of the Subject Company | Contract Clinical Testing |
| Location of the Subject Company | Minami-ku, Hiroshima, Hiroshima Prefecture |
| Capital Stock of the Subject Company | 12,500万円 |
| Date of Establishment of the Subject Company | 3 September 2012 |
| Net Sales of the Subject Company | 25,880千円（2024年５月期） |
| Operating Profit of the Subject Company | △66,125千円（2024年５月期） |
| Net Income of the Subject Company | △65,266千円（2024年５月期） |
| Net Assets of the Subject Company | △141,522千円（2024年５月期） |
| Acquisition price | 譲渡価額：非公表とさせていただきます（株主が個人であり、株式譲渡契約書における守秘義務をふまえ） |
| Number of shares acquired | 738,133株（議決権の数：738,133個） |
| Voting rights ownership percentage | Before 82.5％ → after －％ |
| Impact on Business Performance | 現在精査中であり、他の要因も含め、見通しが明らかになり次第、速やかに公表いたします。 |
| Date of board resolution | 2025年３月27日 |
| Contract Date | 2025年３月27日 |
| Execution Date / Effective Date | 2025年３月28日（予定） |
| Valuation methodology | 公正なプロセスを経て株式譲渡相手先との交渉により決定 |
Items this document does not state (13)
Expenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Independent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.ミルテルの売上拡大や収益化のスピードが当初計画を下回り、想定していた歯科領域でのシナジー効果を得ることも困難な状況となったため、経営資源の選択と集中により企業価値の向上を図るとしている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.